

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner
 US Department of Commerce
 United States Patent and Trademark
 Office, PCT
 2011 South Clark Place Room
 CP2/5C24
 Arlington, VA 22202
 ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 21 December 2000 (21.12.00)	Applicant's or agent's file reference case: 4104
International application No. PCT/SE00/01029	Priority date (day/month/year) 31 May 1999 (31.05.99)
International filing date (day/month/year) 23 May 2000 (23.05.00)	
Applicant HALL, Jan et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

01 December 2000 (01.12.00)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Charlotte ENGER Telephone No.: (41-22) 338.83.38
--	--

TITLE

Method, arrangement and use of an implant for ensuring
delivery of bioactive substance to the bone and/or
5 tissue surrounding the implant.

TECHNICAL FIELD

The present invention relates to a method for
use in connection with an implant for bone and/or
10 tissue structure, for example dentine, and ensuring
delivery of bioactive substance to the structure during
all or part of the period of incorporation of the
implant. The invention also relates to an arrangement
and use of such an implant and such delivery.

15

PRIOR ART

In connection with implants, it is already
known to use various types of bioactive substances
intended to improve the incorporation of the implant in
20 the bone or tissue in question. Thus, for example, it
may be desirable to use a substance belonging to the
superfamily TGF- β , for example so-called BMP (Bone
Morphogenetic Proteins) in order to initiate and
stimulate bone growth. Reference may be made here to
25 patent publications WO 95/33502, WO 96/40014 and
WO 98/17330, among others.

Implants and implant elements and methods for
permanent anchoring in mineralized tissue have been
known for a long time. To prevent the implant from
30 coming loose, it is important to establish direct
contact (i.e. direct application) between the outer
surface of the implant or implant element and the
surrounding body tissue. When direct application has
indeed been established, the implant is stable, and so-
35 called osseointegration can be obtained. Direct contact
between the surface of the implant element and the bone
tissue can be obtained by means of a suitable implant
structure and refined surgical technique. The principle
of osseointegration has been developed by Professor

Brånemark et al. and has been used successfully in the treatment of edentulous patients with dental implants for many years.

The treatment of edentulous patients usually includes careful patient selection, a detailed surgical protocol, and careful planning of the prosthetic constructions which are to be used. The most successful clinical results have been achieved after treatment of patients with tight, compact bone in which it is fairly easy to obtain stable fixation of the implant. However, less successful results have been reported after treatment in bone of softer quality. The difficulties have manifested themselves in the break-up of a stable implant fixation. Various methods have been proposed to overcome these difficulties. These methods generally involve using additional new means for implant surfaces, for example coating with hydroxyapatite, or preparation of implant surface irregularities which have been judged to improve the implant fixation. Very little is in fact known of the relative importance of implant geometry, chemical surface properties and surface irregularities. However, implant geometry probably plays an important role, since it has a strong influence on the load distribution in the tissue surrounding the implant body.

Running parallel with the development of different types of implants, investigations have been conducted with the aim of characterizing the interaction of cells and cellular molecules in living tissue. Detailed analysis of the interaction at the cellular and molecular level has been found to be fundamental for the development of the modern pharmaceutical industry and genetic engineering. However, such knowledge could also be successfully used in the development of load-bearing implants in bone. When the mechanisms of interaction are known, it may be possible to act on the processes of interaction and the possibilities of stimulating bone growth and increasing bone density and bone volume in or at the implant site

in the body. This is often a precondition for stable implant fixation in less than optimal circumstances with soft bone qualities.

5 A particular example of acting on bone growth and increasing bone density is the use, as mentioned above, of bioactive substances. Growth factors can stimulate bone growth in a known manner, provided that they are released into the surrounding tissue at a sufficient concentration and speed for a fairly long
10 period of time after their introduction.

Insofar as reference is made to the said Brånemark system, reference may also be made, inter alia, to European Patent Application 95102381.1 (676179).

15 Implants as such are already very well known and are commercially available in large numbers and in many different ranges. Implants which are relevant in this context are disclosed, for example, in US Patent Specification 4,960,301, as well as implants which are
20 shown in the publication "Oral Implantology" which relates to "ITI Hollow Cylinder System", published 1991 by Georg Thieme Verlag, Stuttgart and New York.

Studying and/or acting on the anchoring of implants in living biological tissues under variable
25 conditions, especially in the form of reaction to locally applied substances, is the subject of European Patent Specification 720833. This arrangement comprises an anchoring element which is to be incorporated in the tissue. It has a central recess in the form of a depot
30 for the substance in question. The surface of the anchoring element adjoining the tissue consists entirely or partially of penetrable material or "filter" which allows the applied substance to diffuse out onto the implant surface, or into the biological
35 fluid around the implant surface, from a central recess. Although it is stated that such an anchoring element would simulate clinically produced implants with respect to material and/or surface properties, implantation positions and surgical technique, it must

be appreciated that this type of anchoring element, with its depot for providing the substance and with a separate filter element, is less attractive for permanent anchoring when it is used as a conventional
5 implant element. Specifically, the introduction of the active substance in solid form or liquid form in a specific depot and a filter element, through which the active substance is allowed to diffuse, is less
10 suitable and means that this type of implant arrangement is more suited for test purposes than for long-term clinical use.

DESCRIPTION OF THE INVENTION

TECHNICAL PROBLEM

15 In connection with implants of the type in question, it is important to establish an appropriate substance layer function at and in connection with the implant. The main object of the invention is to solve this problem, among others.

20 It is important to be able to use tried and tested experience with proven and effective implant structures without essentially affecting these in other respects. The invention solves this problem too.

In connection with clinically well-designed
25 implants, it is important to be able to achieve an effective use and release function for the bioactive substance in question, all of which substance must be able to be used effectively. In various designs, it is also important to be able to control the release
30 function during the incorporation process, for example so that an initially high release function is available during a first time period and a lower release function is obtained during a second time period, or vice versa. The variations in question must be able to be effected
35 by choice of differently structured implants in terms of the support function for the bioactive substance arranged in the respective implant. The invention solves this set of problems too.

One object of the invention is thus to combine the properties of clinically efficient implant elements and clinically efficient supports for growth factors, by modifying the geometry of existing implant elements in order to obtain secure containment of the substance in the element. Such a novel implant element can permit rapid incorporation of surrounding tissue and stable fixation even in non-optimal bone qualities, and it does this by virtue of the stimulation activity from the growth factors which are released from the support or body.

A further object of the invention is to make available an implant element with an external structure which is similar to or corresponds to the clinically efficient implant elements, so-called fixtures, which permit positioning of efficient supports or bodies with respective growth factors and a sought release of these growth factors into the tissue which is stored in the body of the implant element. Such a combination of implant element and support permits stimulation of bone growth in the tissue surrounding the implant element and also rapid incorporation and stable fixation of the implant elements in mineralized tissue.

SOLUTION

The features which can principally be regarded as characterizing a method according to the invention are that the implant is designed with an internal space and, if appropriate, one or more channels and/or recesses leading from the internal space to the outside or outside part of the implant facing towards the structure, that one or more bodies comprising the bioactive substance are designed to cooperate with the bone and/or tissue structure surrounding the implant so as to be able to release the bioactive substance to the said surrounding structure. Further characteristics are that the said body or bodies is/are applied in the said space and, if appropriate, also in one or more of the said channels and/or recesses, in order thereby to be

exposed to the said surrounding structure and deliver the bioactive substance to the latter during the said period.

5 An arrangement according to the invention can principally be regarded as being characterized in that the implant is designed with one or more internal spaces and, if appropriate, one or more channels or recesses which lead from the internal space or spaces to the outside of the implant. Further characteristics
10 are that one or more bodies comprising the bioactive substance are designed to cooperate with the surrounding bone and/or tissue structure so as to release the bioactive substance to the surrounding structure, and that the body or bodies is/are assigned
15 a position or positions in the space or spaces in which they are exposed for the said cooperation and release directly or via the said channel(s) or recess(es).

In one embodiment, each body is in the form of a spongy body or cloth saturated in or treated with the
20 bioactive substance. Alternatively, the body can be in the form of a gel which comprises the bioactive substance. The spongy body, the cloth or the gel has a softness which permits distinct application in the space concerned while at the same time ensuring that it
25 is held in place by frictional cooperation, adhesive cooperation, etc., with the wall of the respective space. In a preferred embodiment, the implant or implant element has clinically effective geometrical properties, for example in the shape of a cylindrical
30 or conical solid with an outer surface which is in direct contact with the surrounding body tissue.

The bioactive substance can be a substance belonging to the superfamily TGF- β . In a preferred
embodiment, the implant element has a threaded outer
35 surface and a conically narrowing part. The latter part has an open section with an axial hole or recess for the said support or body. The hole or recess is open towards the end surface of the conical part. One or more through-holes communicate with the said axial

holes and extend radially through the implant body part at right angles to the longitudinal axis of the implant in order to permit direct release of bioactive substance from the said support through the said holes or openings.

The internal space in question can thus comprise a mouth part or recess part with identical cross-sectional areas, and the body or support can fill both the internal space and the recess.

10 In one embodiment, the said axial hole can extend from the conical part through the main part of the implant body in order to permit release of growth factors along the length of the implant body through a suitable number of holes, channels and/or recesses in
15 the wall of the implant element. The design and structure of the body/support or bodies/supports are chosen on the basis of a predetermined or anticipated release function. A first body can assume a first position in which the first body is arranged with a
20 first degree of exposure, and a second body assumes a second position in which the second body has a second degree of exposure less than the first degree of exposure, or vice versa, for the purpose of permitting a controlled or optimum release function for the
25 bioactive substance in question.

Alternatively, each body can be arranged in such a way that, in the said cooperation and release function, it varies the degree of release of the bioactive substance during the release period and, for
30 example, effects a greater degree of release at the start of the period, or vice versa. In a further embodiment of the element, the design(s) or extent(s) of the space or spaces and any associated channels or recesses are chosen on the basis of a predetermined or
35 anticipated release function. The channels or recesses can be arranged with different cross-sectional areas and/or extents, which means that different parts of the same body or different bodies are subject to different degrees of exposure in the release function, for the

purpose of permitting a controlled or optimum release function for the implant situation in question. In a further embodiment, two bodies can be situated at a distance from each other inside the implant or implant element in order to serve different parts of the surrounding bone and/or tissue structure. The body can be absorbable in association with the release of substance. The body (bodies) can first be applied in the space and thereafter saturated with substance, which saturation can be effected with substance at different concentrations and/or quantities for the purpose of achieving a predetermined or anticipated release function.

A use according to the invention can principally be regarded as being characterized in that the implant is used to support, in one or more internal spaces, one or more bodies comprising the bioactive substance, and, via possible attachments to the space or spaces, to expose the body or bodies in order to release the bioactive substance to the surrounding bone and/or tissue structure.

ADVANTAGES

By means of what has been proposed above, a novel aid is obtained for use in surgery for the purpose of obtaining effective incorporation processes in tissue, for example bone tissue. An implant according to the invention, provided with support(s) or body (bodies), can be made commercially available. Alternatively, the implant and support/body/bodies can be made available separately and joined together in situ by the person concerned, for example the surgeon. Various types of supports with different release functions and release times can be included within one range. Various types of implants or implant elements with different systems of channels and internal spaces can be made available in order to permit different release functions and release times. In addition, each body can be saturated with substance in a different

quantity and/or concentration. Well-proven surgical procedures, substances and implant designs can be used in different implantation situations, which can include implantation in hard or soft dentine.

5

DESCRIPTION OF THE FIGURES

A presently proposed embodiment of a method, arrangement and use according to the present invention will be described below with reference to the attached drawings, in which

Figure 1 shows, in vertical section, the cooperation between bioactive substance, included in a body or support, and bone tissue which is shown diagrammatically and in which biological organisms and fluids are present,

Figure 2 shows, in block diagram form, the production of an implant with body or support with bioactive substance, chosen from a range of differently constructed implants and a range of differently constructed bodies/supports designed with different release functions,

Figure 3 shows a time diagram of the release function for implants with different supports,

Figure 4 shows, in vertical section, a first system of channels and internal spaces in an implant, and bodies/supports arranged in the latter,

Figure 5 shows, in vertical section, a second design of the internal spaces and channel system,

Figure 6 shows, in vertical section, a first structural design of an implant with internal space for body/support,

Figure 7 shows, in perspective and obliquely from above, a body or support with growth factors which is intended to be inserted into an implant according to Figure 7,

Figure 8 shows, in vertical section, the implant according to Figure 7, but turned through 90° in relation to Figure 7, and

Figure 9 shows, in vertical section, a second design of an implant.

DETAILED EMBODIMENT

5 In Figure 1, a support for bioactive substance in accordance with the above is indicated by reference number 1. The body or support 1 can be in the form of a sponge which is saturated with the said bioactive substance. Alternatively, the support or body can
10 comprise a gel. The body or support is shown separately (i.e. without implant) in relation to a surrounding bone and/or tissue structure which has been symbolized by 2. The body must be of such a type that it can cooperate with the structure 2 so that its bioactive
15 substance can be released to the surrounding structure 2 in question. The release function is initiated by the biological organisms and fluids of the structure. It may also be assumed that the bioactive substance introduced into the body or support 1 or applied onto
20 the body or support causes, by virtue of its high concentration, a concentration diffusion across to the structure. In the figure, the said cooperation is shown by dual-direction arrows 3, 4 and 5. The cooperation between the bioactive substance and the structure may
25 be assumed to work in both directions.

In Figure 2, reference number 6 indicates an implant or implant element, into which a body or support 1' with bioactive substance is inserted. The body is spongy or soft and can be pressed into the
30 recess of the implant in question, which recess is indicated by 7. A distinct and clear position of the body 1' in the recess 7 can be obtained by means of friction between the outside 1a or outer surface of the body 1 and the inner wall 7a of the recess. In addition
35 to this, or alternatively, a securing means, for example an adhesive paste 8, can be used. The said implant 1' is chosen from a range of implants, which range is indicated by 9. In the range of implants, the various implants have different designs, for example

different internal spaces 10, 11 and different systems of channels or recesses 12, 13. The body or support 1' is chosen from a range of bodies or supports, which range is indicated by 14. The bodies or supports can be
5 designed for different release functions for bioactive substances applied on the bodies. Likewise, the system of channels and spaces can be arranged so that these give the respective body in the respective implant different degrees of exposure, for the purpose of
10 producing different, controlled and/or optimal release times.

In Figure 3, examples of the said release functions are shown in diagram form. The vertical axis shows the quantity of bioactive substance released, and
15 the horizontal axis shows the time. Different curves 15 and curve combinations 16, 17 and 18 can be established on the basis of the said choices from the ranges 9 and 14. The outer surface of the implant is indicated by 6a.

20 Figure 4 shows surrounding body tissue 2', and an implant which has been inserted into the tissue is indicated by 6'. The implant is designed with a space 7', and in this space there are three bodies/supports with bioactive substances, indicated by 19, 20 and 21.
25 The bodies or supports communicate with the surrounding tissue 2' via channels 22, 23 and 24, respectively, and the cooperation with the surrounding tissue is indicated by 25, 26 and 27. The lowermost body 21 also cooperates, via a larger recess, with the surrounding
30 tissue in the direction of the arrow 28.

Figure 5 illustrates the case where a number of spaces 29 and 30 are provided. The space 29 communicates with the tissue 2'' via one or more channels 31, the cooperation being indicated by 32. The
35 space 30 cooperates directly with the tissue 2' in the direction of arrow 33. The body in the space 29 is indicated by 34, and the body in the space 30 is indicated by 35.

The implant element according to Figure 6 represents a modification of an implant fixture in the well-known Brånemark System® which consists of a general cylindrical, solid titanium body part with a threaded outer surface 37 and a conical end part 38. The implant fixture further consists of a head part 39 with an anti-rotation design in the form of a hexagon 40 which can be acted on using a suitable turning tool. The head part also consists of a smaller conical flange 41 and a central threaded inner hole 42 for the tightening screw (not shown) which extends along the longitudinal axis of the implant. The end part 38 has an open section which, in this example, comprises an axial hole or recess 43 which is open towards the end surface, and a through-hole 44 which communicates with the said hole 43 and extends radially through the implant body at right angles to the axis of the implant. As is indicated, a second through-hole 44' can also be formed in the body section such that the two holes are at right angles to each other.

The width dimension D of the body part of the implant fixture is in the range of 3.7 mm to 6.0 mm. In this illustrative embodiment, D is about 5.0 mm, and the length of the implant fixture is about 10 mm. The diameter d of the axial hole 43 is 3 mm, and the depth is 4 mm. The transverse hole 44 has a diameter of 2 mm, and the holes are drilled through the implant body. The threaded inner hole 42 for the Brånemark System® implant fixture which is used in this particular example is 6 mm in depth along the implant axis. The inner hole 42 thus sets a limit for the maximum possible depth of the 3 mm axial hole 43.

Compared with the standardized Brånemark System® implant fixture, and also compared with other known implant fixtures of this type available on the market, the main modification in the illustrated implant fixture lies in the axial opening or hole 43. The geometric limitation on this hole is defined by the implant diameter D and the depth of the inner hole 42.

The minimum depth of the hole 43 is preferably not less than 1.5 x the hole diameter. However, a factor of 1.25 is used in many successful clinical cases.

A modification of the implant fixture according to Figure 6 permits a body or support for growth factors to be fitted in the axial hole 43 of the implant body part. Figure 2 shows such a support in the form of a sponge, and Figure 8 shows the implant fixture according to Figure 6 when the sponge has been fitted in it. In this particular example of the invention, an absorbent collagen sponge 45 has been used as support. Such a sponge has an elastic, porous mass and absorbs the said biological substance. In the case shown, the sponge has a thickness of 4 mm and a circular configuration with a diameter d_{sp} of approximately 3.1 mm. It can be easily fitted in the axial hole 43 by hand or using a suitable instrument.

Collagen sponge materials in the form of bands, strips, blades or the like with different thicknesses and qualities are available on the market. A punch (not shown) is used to make bodies from the sponge material, in this case circular units with a diameter matching the diameter d of the axial hole 43.

The collagen part is fitted by hand into the hole 43 of diameter 3 mm in the implant body. A number of tests have been carried out to obtain reliable fixing of the sponge, in which tests the sponge was either dry or saturated with bioactive substance. These tests showed that the diameter d_{sp} ought to be in the range of $3.0 \text{ mm} < d_{sp} < 3.2 \text{ mm}$, both in the dry state and in the wet state.

The secure fixing of the sponge thus makes it possible for liquid containing growth factors to be added to the sponge after the latter has been fitted in the axial hole 43. The modified design of the implant makes it possible to release growth factors through the three holes or openings shown, namely the axial opening 43 and the two perpendicular openings 44. In accordance with the chosen terminology used in the attached patent

claims, the recess or hole 43 constitutes an inner space for the body or support. The outer part of the space 43 can be regarded as constituting a channel adjacent to the actual space. In the present case according to Figure 8, the body or support 45 thus fills both the inner space and the recess or channel in question.

As the growth factors are released to the surrounding bone or surrounding tissue in accordance with the above, it stimulates bone growth or bone growth introduction in the area of the implant. As the collagen sponge is absorbable in itself, it is replaced by newly formed bone within the implant during the absorption process.

As regards the growth factors or the biological substances, these are applied to the sponge in the form of a liquid. A conventional injection instrument or hand pump instrument can be used to apply the desired quantity of liquid to the sponge. As regards the BMP mentioned earlier, this is a human protein which stimulates bone growth and is an example of the growth factors which can be used in the present invention. In particular, it is possible to use known growth factors of the types BMP 2 and BMP 4 which have been identified by the Genetics Institute INC as being suitable in this case. Suitable doses can be obtained from combined systems of implants and sponges with added substance, depending on the status of the bone in the implantation site, which can vary considerably from one case to another. Different concentrations of substance can be applied to the sponge in order to effect a considerable increase in bone growth in the area of the implant.

As regards the structure of the modified implant element which has been described thus far, it will be appreciated that instead of two radial holes 44 at right angles to each other, it is also possible to use other configurations of holes or channels which communicate with the axial hole 43 and open out onto the threaded outer surface. In the illustrative

embodiment shown, the release of growth factors is more or less concentrated in the area around the pointed part of the implant body. In the case of an implant element without the said threaded upper hole for a tightening screw, i.e. an implant element which is designed for an external tightening means, or with only a short hole 42, the axial hole 43 can be made much deeper and can extend through the head part of the longitudinal implant body. In such a case, the growth factors can be released along the length of the implant element, through a suitable number of holes or channels 46 in the wall of the implant element (see Figure 9). Alternatively, the sponge support can also be designed as a rod, or one or more sponge strips can be fitted in such a longitudinal hole or in the channel itself.

The invention is not limited to the embodiment described above by way of example, and instead it can be modified within the scope of the attached patent claims and the inventive concept. Thus, for example, the invention is not limited to the bodies or supports in the embodiment described above. Supports in the form of gels, solid bodies, liquids or the like can be used, provided that their dimensions and/or the viscosity permits fixing to the implant configuration in question. In the illustrative embodiment, a standard fixture has been modified in order to permit insertion of a suitable support for bioactive substances, in order to obtain a combination of implant and support which permits advantageous release of the bioactive substances into the tissue surrounding the implant element.

PATENT CLAIMS

1. Method for use in connection with an implant
5 (6) for bone and/or tissue structures, for example the
jaw bone, ensuring delivery of bioactive substance to
the structure during all or part of the period of
incorporation of the implant, characterized in that the
10 implant is designed with an internal space (7) and, if
appropriate, one or more channels and/or recesses (22,
23, 24) leading from the internal space to the outside
(6a) or outside part of the implant facing towards the
structure, in that one or more bodies comprising the
15 bioactive substance are designed to cooperate with the
bone and/or tissue structure surrounding the implant so
as to be able to release the bioactive substance to the
said surrounding structure, and in that the said body
or bodies (1) is/are applied in the said space and, if
20 appropriate, also in one or more of the said channels
and/or recesses, in order thereby to be exposed to the
said surrounding structure and deliver the bioactive
substance to the latter during the said period, the
bioactive substance being applied before and/or after
25 application of the body (or bodies) in the space (or
spaces).

2. Arrangement for use in connection with an
implant (6) for bone and/or tissue structure (2), for
example the jaw bone, ensuring delivery (3, 4, 5) of
bioactive substance to the structure surrounding the
30 implant during all or part of the period of
incorporation of the implant in the structure,
characterized in that the implant is designed with one
or more internal spaces (29, 30) and, if appropriate,
one or more channels or recesses which extend from the
35 internal space or spaces to the outside of the implant,
in that one or more bodies comprising bioactive
substances are designed to cooperate (3, 4, 5) with the
surrounding bone and/or tissue structure (2) so as to
release the bioactive substance to the surrounding

structure, and in that the body or bodies is/are assigned a position or positions in the space or spaces in which they are exposed for the said cooperation and release.

5 3. Arrangement according to Patent Claim 2, characterized in that each body (1) is in the form of a spongy body or cloth saturated in or treated with bioactive substance, or a gel which comprises the bioactive substance, and in that the spongy body, the
10 cloth or the gel has a softness which permits distinct application in the space concerned while at the same time ensuring that it is held in place by frictional cooperation, adhesive cooperation, with the inner wall of the respective space.

15 4. Arrangement according to Patent Claim 2 or 3, characterized in that the implant has clinically effective geometrical properties and has the shape of a cylindrical or conical solid with an outer surface for direct contact with the body tissue (2).

20 5. Arrangement according to Patent Claim 2, 3 or 4, characterized in that the implant element consists of an absorbable collagen sponge.

6. Arrangement according to any of Patent Claims 2 to 5, characterized in that the bioactive substance is
25 a substance belonging to the superfamily TGF- β .

7. Arrangement according to any of Patent Claims 2 to 6, characterized in that the implant or the implant element has a body part with a threaded outer surface and a conical tip, the said tip having an open section
30 with an axial hole or recess for the said body, which hole or recess is open towards the end surface of the tip part, and one or more through-holes which communicate with the said axial holes and extend radially through the implant body part at right angles
35 to the longitudinal implant axis in order to permit direct release of the bioactive substance from the said body through the said holes or openings.

8. Arrangement according to any of Patent Claims 2 to 7, characterized in that the axial hole extends from

the tipped end part through the main part of the implant body in order to permit release of growth factors along the length of the implant body part through a suitable number of channels or recesses in the wall of the implant or implant element.

9. Arrangement according to any of Patent Claims 2 to 8, characterized in that the design(s) and structure(s) of the body or bodies are chosen on the basis of predetermined release functions.

10. Arrangement according to any of Patent Claims 2 to 9, characterized in that a first body assumes a first position in which the first body is arranged with a first degree of exposure of a certain substance, and a second body assumes a second position in which the second body has a second degree of exposure of the same substance, or of another substance, less than the first degree of exposure, or vice versa, for the purpose of permitting a controlled or optimum release function in the implant situation in question.

11. Arrangement according to any of Patent Claims 2 to 10, characterized in that each body is arranged in such a way that, in the said cooperation and release function, it varies the degree of release of bioactive substance and, for example, effects a greater degree of release at the start of the period than at the end of the period, or vice versa.

12. Arrangement according to any of Patent Claims 2 to 11, characterized in that the design(s) or extent(s) of the space or spaces and any associated channels or recesses are chosen on the basis of a predetermined or anticipated release function.

13. Arrangement according to any of Patent Claims 2 to 12, characterized in that the channels or recesses are arranged with different cross-sectional areas and/or extents, which means that different parts of the same body or different bodies are subject to different degrees of exposure in the release function, for the purpose of permitting a controlled or optimum release function for the bioactive substance or substances.

14. Arrangement according to any of Patent Claims 2 to 13, characterized in that two bodies are situated at a distance from each other in order to serve different parts of the surrounding bone and/or tissue structure.

5 15. Arrangement according to any of Patent Claims 2 to 14, characterized in that each implant with associated body/bodies can be built up or chosen from a number of implants which vary in respect of the spaces and any recesses and/or channels, and/or from a number
10 of different bodies having different properties in respect of the release function and substances.

16. Arrangement according to any of Patent Claims 2 to 15, characterized in that each body can be introduced into the respective space and, after
15 introduction, can be saturated with bioactive substance, for example by means of an injection needle or a hand pump.

17. Use of an implant which can be fitted in bone and/or tissue structure, for example the jaw bone,
20 ensuring delivery of bioactive substance to the structure surrounding the implant during all or part of the period of incorporation of the implant in the structure, characterized in that the implant is used to support, in one or more internal spaces, one or more
25 bodies comprising the bioactive substance, and to expose the body or bodies to the surrounding structure and, in cooperation with the structure, to release the bioactive substance to the latter.

1 / 3

Fig. 1




Fig. 2





Fig. 3



2 / 3

Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 9





Fig. 8



PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 4104 PCT	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/SE00/01029	International filing date (<i>day/month/year</i>) 23.05.2000	Priority date (<i>day/month/year</i>) 31.05.1999
International Patent Classification (IPC) or national classification and IPC ₇ A61C 8/00, A61L 27/04, A61L 27/54		
Applicant Nobel Biocare AB (publ) et al		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 4 sheets, including this cover sheet.
- ☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of _____ sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand 01.12.2000	Date of completion of this report 09.10.2001
Name and mailing address of the IPEA/SE Patent- och registreringsverket Box 5055 S-102 42 STOCKHOLM Facsimile No. 08-667 72 88	Authorized officer Jack Hedlund/EK Telephone No. 08-782 25 00

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/SE00/01029

I. Basis of the report

1. With regard to the elements of the international application:*

- ☒ the international application as originally filed
- ☐ the description:
pages _____, as originally filed
pages _____, filed with the demand
pages _____, filed with the letter of _____
- ☐ the claims:
pages _____, as originally filed
pages _____, as amended (together with any statement) under article 19
pages _____, filed with the demand
pages _____, filed with the letter of _____
- ☐ the drawings:
pages _____, as originally filed
pages _____, filed with the demand
pages _____, filed with the letter of _____
- ☐ the sequence listing part of the description:
pages _____, as originally filed
pages _____, filed with the demand
pages _____, filed with the letter of _____

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.
These elements were available or furnished to this Authority in the following language _____ which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. ☐ The amendments have resulted in the cancellation of:

- ☐ the description, pages _____
- ☐ the claims, Nos. _____
- ☐ the drawings, sheet/fig _____

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2 (c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item I and annexed to this report.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/SE00/01029

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application,

☒ claims Nos. 17

because:

☒ the said international application, or the said claims Nos. 17
relate to the following subject matter which does not require an international preliminary examination (*specify*):

See PCT Rule 67.1 (iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. _____
are so unclear that no meaningful opinion could be formed (*specify*):

☐ the claims, or said claims Nos. _____ are so inadequately supported
by the description that no meaningful opinion could be formed.

☐ no international search report has been established for said claims Nos. _____

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the standard.

☐ the computer readable form has not been furnished or does not comply with the standard.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/SE00/01029

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**1. Statement**

Novelty (N)	Claims	<u>1-16</u>	YES
	Claims		NO
Inventive step (IS)	Claims	<u>1-16</u>	YES
	Claims		NO
Industrial applicability (IA)	Claims	<u>1-16</u>	YES
	Claims		NO

2. Citations and explanations (Rule 70.7)

Cited documents:

1. WO 9640014 A1 (DANEK MEDICAL, INC.)
2. WO 9817330 A1 (SDGI HOLDINGS, INC.)

The documents cited in the International Search Report represent background art.

The invention defined in claims 1 - 16 is not disclosed by any of these documents.

None of the cited documents gives any indication towards the claimed method for use in connection with an implant for ensuring delivery of bioactive substance. No relevant combination of the cited documents would lead a person skilled in the art to the invention defined in the claims.

Therefore, the invention defined in claims 1 - 16 is novel and is considered to involve an inventive step. It is also considered to be industrially applicable.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE00/01029

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: **17**
because they relate to subject matter not required to be searched by this Authority, namely:
See PCT Rule 39.1(iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).:

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 00/01029

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61C 8/00, A61L 27/04, A61L 27/54

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A61C, A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 9640014 A1 (DANEK MEDICAL, INC.), 19 December 1996 (19.12.96) --	1-16
A	WO 9817330 A1 (SDGI HOLDINGS, INC.), 30 April 1998 (30.04.98) -- -----	1-16

☐

Further documents are listed in the continuation of Box C.

☒

See patent family annex.

* Special categories of cited documents

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

18 Sept. 2000

Date of mailing of the international search report

20 -09- 2000

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Jack Hedlund/E1s

Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

Information on patent family members

01/08/00

International application No.

PCT/SE 00/01029

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
WO	9640014	A1	19/12/96	AU	5954096 A	30/12/96
				EP	0836454 A	22/04/98
				US	5702449 A	30/12/97
				US	6039762 A	21/03/00

WO	9817330	A1	30/04/98	AU	4985197 A	15/05/98
				EP	0934087 A	11/08/99
